4.7 Article

Severe Morbidity and Mortality Associated With Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults

期刊

CLINICAL INFECTIOUS DISEASES
卷 69, 期 2, 页码 197-203

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciy991

关键词

respiratory syncytial virus; influenza; adult; hospitalization; mortality

资金

  1. Novavax, Inc., Gaithersburg, MD

向作者/读者索取更多资源

Background. Respiratory syncytial virus (RSV) is an important cause of serious respiratory illness in older adults. Comparison of RSV and influenza infection in hospitalized older adults may increase awareness of adult RSV disease burden. Methods. Hospitalized adults aged >= 60 years who tested positive for RSV or influenza between 1 January 2011 and 30 June 2015 were identified from Kaiser Permanente Southern California electronic medical records. Baseline characteristics, comorbidities, utilization, and outcomes were compared. Results. The study included 645 RSV- and 1878 influenza-infected hospitalized adults. Patients with RSV were older than those with influenza (mean, 78.5 vs 77.4 years; P =.035) and more likely to have congestive heart failure (35.3% vs 24.5%; P <.001) and chronic obstructive pulmonary disease (COPD) (29.8% vs 24.3%; P =.006) at baseline. In adjusted analyses, RSV infection was associated with greater odds of length of stay >= 7 days (odds ratio [OR] = 1.5; 95% confidence interval [CI], 1.2-1.8; P <.001); pneumonia (OR = 2.7; 95% CI, 2.2-3.2; P <.001); intensive care unit admission (OR = 1.3; 95% CI, 1.0-1.7; P =.023); exacerbation of COPD (OR = 1.7; 95% CI, 1.3-2.4; P =.001); and greater mortality within 1 year of admission (OR = 1.3; 95% CI, 1.0-1.6; P =.019). Conclusions. RSV infection may result in greater morbidity and mortality among older hospitalized adults than influenza. Increased recognition of adult RSV disease burden will be important in the evaluation and use of new RSV vaccines and antivirals.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Letter Immunology

Reply to Chu et al

Bradley Ackerson, Katia Bruxvoort, Lei Qian, Lina S. Sy, Hung Fu Tseng

JOURNAL OF INFECTIOUS DISEASES (2023)

Article Immunology

Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 (COVID-19) in Immunocompetent Adults

Ana Florea, Lina S. Sy, Lei Qian, Bradley K. Ackerson, Yi Luo, Julia E. Tubert, Gina S. Lee, Jennifer H. Ku, Katia J. Bruxvoort, Carla A. Talarico, Sijia Qiu, Yun Tian, Hung Fu Tseng

Summary: Among immunocompetent adults, the mRNA-1273 booster provides additional protection against SARS-CoV-2 infection and severe COVID-19 disease compared to the 2-dose mRNA-1273 primary series during periods of Delta and Omicron predominance.

CLINICAL INFECTIOUS DISEASES (2023)

Article Immunology

A safety study evaluating non-COVID-19 mortality risk following COVID-19 vaccination

Stanley Xu, Runxin Huang, Lina S. Sy, Vennis Hong, Sungching C. Glenn, Denison S. Ryan, Kerresa Morrissette, Gabriela Vazquez-Benitez, Jason M. Glanz, Nicola P. Klein, Bruce Fireman, David McClure, Elizabeth G. Liles, Eric S. Weintraub, Hung -Fu Tseng, Lei Qian

Summary: We conducted a large cohort study to evaluate the risk of non-COVID-19 mortality after COVID-19 vaccination. The results showed that the non-COVID-19 mortality rates among COVID-19 vaccinees were lower than those among comparators, and no increased risk was found for non-COVID-19 mortality among recipients of the three COVID-19 vaccines used in the US.

VACCINE (2023)

Article Multidisciplinary Sciences

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5

Hung Fu Tseng, Bradley K. Ackerson, Katia J. Bruxvoort, Lina S. Sy, Julia E. Tubert, Gina S. Lee, Jennifer H. Ku, Ana Florea, Yi Luo, Sijia Qiu, Soon Kyu Choi, Harpreet S. Takhar, Michael Aragones, Yamuna D. Paila, Scott Chavers, Carla A. Talarico, Lei Qian

Summary: This study evaluates the effectiveness of the mRNA-1273 (Moderna) vaccine for Omicron subvariants based on data from the USA. It shows that while effectiveness against infection decreases rapidly after the third and fourth doses, effectiveness against hospitalization remains high. The study also suggests reduced neutralization against omicron BA.4/BA.5 compared to earlier omicron subvariants.

NATURE COMMUNICATIONS (2023)

Article Infectious Diseases

Investigating Tetanus, Diphtheria, Acellular Pertussis Vaccination During Pregnancy and Risk of Congenital Anomalies

Ana Florea, Lina S. Sy, Bradley K. Ackerson, Lei Qian, Yi Luo, Tracy Becerra-Culqui, Gina S. Lee, Yun Tian, Chengyi Zheng, Radha Bathala, Sara Y. Tartof, Laura Campora, Maria Angeles Ceregido, Anastasia Kuznetsova, Jean-Etienne Poirrier, Dominique Rosillon, Laura Valdes, Brigitte Cheuvart, Narcisa Mesaros, Nadia Meyer, Adrienne Guignard, Hung-Fu Tseng

Summary: This study evaluated the risk of congenital anomalies in infants following prenatal vaccination with the Tdap vaccine. The results showed a significantly increased risk of congenital anomalies in certain body systems among vaccinated women. However, these findings may be attributed to improved diagnosis rather than a direct association with the vaccine.

INFECTIOUS DISEASES AND THERAPY (2023)

Article Immunology

Safety of measles, mumps, and rubella vaccine in adolescents and adults in the vaccine safety Datalink

Kayla E. Hanson, Mona Marin, Matthew F. Daley, Lisa A. Jackson, Lina S. Sy, Nicola P. Klein, Malini B. DeSilva, Lakshmi Panagiotakopoulos, Eric Weintraub, Edward A. Belongia, Huong Q. McLean, Holly C. Groom

Summary: This study aimed to investigate the safety of the measles, mumps, and rubella vaccine (MMR) in adolescents and adults. The results showed that serious adverse events after MMR were rare in this age group, but individuals should be informed about the potential occurrence of local and systemic non-serious adverse events.

VACCINE: X (2023)

Article Anesthesiology

Patient characteristics, anaesthetic workload and techniques in the UK: an analysis from the 7th National Audit Project (NAP7) activity survey

A. D. Kane, J. Soar, R. A. Armstrong, E. Kursumovic, M. T. Davies, F. C. Oglesby, L. Cortes, C. Taylor, I. K. Moppett, S. Agarwal, J. Cordingley, J. Dorey, S. J. Finney, G. Kunst, D. N. Lucas, G. Nickols, R. Mouton, J. P. Nolan, B. Patel, V. J. Pappachan, F. Plaat, B. R. Scholefield, J. H. Smith, L. Varney, T. M. Cook

Summary: Detailed knowledge of the surgical population, anaesthetic workload, techniques and behaviors is crucial for monitoring productivity and directing research themes. A recent survey in UK hospitals revealed an increasing burden of age, obesity, and comorbidity in patients requiring anaesthesia care, with a rise in the use of total intravenous anaesthesia. These findings may be influenced by the impact of the COVID-19 pandemic.

ANAESTHESIA (2023)

Article Immunology

Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study

Jennifer H. Ku, Lina S. Sy, Lei Qian, Bradley K. Ackerson, Yi Luo, Julia E. Tubert, Gina S. Lee, Ana Florea, Katia J. Bruxvoort, Carla A. Talarico, Sijia Qiu, Yun Tian, Hung Fu Tseng

Summary: A study found that the 3-dose mRNA-1273 vaccine series is more effective than the 2-dose series, especially among immunocompromised individuals. The study highlights the importance of completing the 3-dose vaccine series for immunocompromised populations.

VACCINE (2023)

Article Immunology

Post-licensure safety study of new-onset immune-mediated diseases, herpes zoster, and anaphylaxis in adult recipients of HepB-CpG vaccine versus HepB-alum vaccine

Bradley Ackerson, Lina S. Sy, Jeff Slezak, Lei Qian, Kristi Reynolds, Runxin Huang, Zendi Solano, William Towner, Sijia Qiu, Sarah R. Simmons, Steven J. Jacobsen, Katia J. Bruxvoort

Summary: This study compared the incidence of immune-mediated diseases, herpes zoster, and anaphylaxis between recipients of HepB-CpG and HepB-alum vaccines. The results showed that there were similar rates of most immune-mediated diseases and herpes zoster between the two groups, except for a slightly higher rate of rheumatoid arthritis. The incidence of anaphylaxis was very low. Therefore, HepB-CpG vaccine does not have significant safety concerns compared to HepB-alum vaccine.

VACCINE (2023)

Article Immunology

Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults in the United States: Interim results from an observational cohort study

Jennifer H. Ku, Lina S. Sy, Lei Qian, Bradley K. Ackerson, Yi Luo, Julia E. Tubert, Gina S. Lee, Ana Florea, Katia J. Bruxvoort, Fagen Xie, Sijia Qiu, Scott Chavers, Carla A. Talarico, Hung Fu Tseng

Summary: We assessed the relative vaccine effectiveness (rVE) of 4 vs. 3 doses of mRNA-1273 against SARS-CoV-2 infection, COVID-19 hospitalization, and death in immunocompetent adults aged >50 years. The adjusted 4 vs. 3-dose rVE for SARS-CoV-2 infection, COVID-19 hospitalization, and COVID-19 hospitalization death were 25.9%, 67.3%, and 72.5%, respectively. The adjusted rVE for SARS-CoV-2 infection ranged from 19.8% to 39.1% across subgroups. The protection provided by four mRNA-1273 doses against COVID-19 outcomes was significant, although rVE varied and declined over time.

VACCINE (2023)

Article Immunology

Risk of herpes zoster following mRNA COVID-19 vaccine administration

Ana Florea, Jun Wu, Lei Qian, Bruno Lewin, Lina S. Sy, I-Chun Lin, Jennifer H. Ku, Hung Fu Tseng

Summary: A cohort study found that there may be an increased risk of herpes zoster (HZ) after receiving mRNA COVID-19 vaccines, especially in individuals aged 50 and over without a history of zoster vaccination. The risk of HZ was increased by 1.14 and 1.12 times within 90 days after receiving the second dose of mRNA-1273 and BNT162b2 vaccines, respectively.

EXPERT REVIEW OF VACCINES (2023)

Article Multidisciplinary Sciences

mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States

Hung Fu Tseng, Bradley K. Ackerson, Lina S. Sy, Julia E. Tubert, Yi Luo, Sijia Qiu, Gina S. Lee, Katia J. Bruxvoort, Jennifer H. Ku, Ana Florea, Harpreet S. Takhar, Radha Bathala, Cindy Ke Zhou, Daina B. Esposito, Morgan A. Marks, Evan J. Anderson, Carla A. Talarico, Lei Qian

Summary: The bivalent mRNA-1273 COVID-19 vaccine was found to be highly effective in preventing hospitalization for COVID-19, medically attended SARS-CoV-2 infection, and COVID-19 hospital death. The relative vaccine effectiveness against hospitalization for COVID-19 was 70.3%, and the protection provided by the bivalent booster lasted for at least 3 months.

NATURE COMMUNICATIONS (2023)

Article Public, Environmental & Occupational Health

Risk Factors for Not Completing a 2-Dose Primary Series of Messenger RNA COVID-19 Vaccination in a Large Health Care System in Southern California: Retrospective Cohort Study

Stanley Xu, Vennis Hong, Lina S. Sy, Katia J. Bruxvoort, Bruno Lewin, Bing Han, Kimberly J. Holmquist, Lei Qian

Summary: This study examined the risk factors for not completing a 2-dose primary series of mRNA COVID-19 vaccination. The results showed that age, gender, race/ethnicity, health insurance, and pre-vaccination health status were all associated with noncompletion. These findings can inform the development of strategies to improve vaccination coverage and completion rates.

JMIR PUBLIC HEALTH AND SURVEILLANCE (2023)

暂无数据